科研論文-康寧杰瑞

科研論文

截至目前，康寧杰瑞擁有或共同擁有全球28項與技術平臺及產品管線相關的專利授權。研發團隊在具有重要影響力的期刊上發表研究論文多篇。

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
了解詳情
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
了解詳情
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
了解詳情
Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4
了解詳情

Structural Basis of a Novel Agonistic Anti-OX40 Antibody

We identified a novel anti-OX40 agonistic antibody DF004, which stimulated the proliferation of human CD4+ T cells in vitro and inhibited tumor growth in a mouse model. Our crystallography structural ...

發表于:
Biomolecules

2022, 12(9), 1209;
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study

KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. This first-in-human phase I study evaluated the safety/tolerability, pharmacokinetics, preliminary efficac...

發表于:
Clinical Cancer Research

2022;28:618–28
Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4

Combinations of immune checkpoint therapies show encouraging results in the treatment of many human cancers. However, the higher costs and greater side effects of such combinations compared with singl...

發表于:
Advanced Science

2021 Oct;8(20):e2102500.
First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Envafolimab is a novel fusion of a humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection. This study explored the safety and feasibility of subcutaneo...

發表于:
The Oncologist

2021;26:e1514–e1525
Subcutaneous envafolimab monotherapy in?patients with?advanced defective mismatch repair/microsatellite instability high solid tumors

Monoclonal antibodies targeting programmed death ligand 1 (PD?L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI?H) tumors must be delivered b...

發表于:
Journal of Hematology & Oncology

2021, 14(1): 95.
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance

Notwithstanding the numerous drugs available for liver cancer, emerging evidence suggests that chemotherapeutic resistance is a significant issue. HGF and its receptor MET play critical roles ...

發表于:
Autophagy.

2019 Jul;15(7):1258-1279.
Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cytokine, induces antitumor effects depending on CD8+ T cells. However, it remains elusive how ...

發表于:
Cancer Cell.

2019 Jun 10;35(6):901-915.e4.
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediate...

發表于:
Molecular Cancer Therapeutics.

2019 Jan;18(1):100-111.
Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

Recently, various immuno-PET tracers based on monoclonal antibodies (mAbs),engineered scaffold proteins, and peptides were developed to target either programmed cell death protein 1 (PD-1) or programm...

發表于:
Molecular Pharmaceutics.

2018 Apr 2;15(4):1674-1681.
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blockingnegative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrationsconsiderably higher than plasma levels achieve...

發表于:
Cell Research.

2018 Apr;28(4):416-432.

1 2

Structural Basis of a Novel Agonistic Anti-OX40 Antibody

We identified a novel anti-OX40 agonistic antibody DF004, which stimulated the proliferation of human CD4+ T cells in vitro and inhibited tumor growth in a mouse model. Our crystallography structural ...

First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study

KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. This first-in-human phase I study evaluated the safety/tolerability, pharmacokinetics, preliminary efficac...

Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4

Combinations of immune checkpoint therapies show encouraging results in the treatment of many human cancers. However, the higher costs and greater side effects of such combinations compared with singl...

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Envafolimab is a novel fusion of a humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection. This study explored the safety and feasibility of subcutaneo...

Subcutaneous envafolimab monotherapy in?patients with?advanced defective mismatch repair/microsatellite instability high solid tumors

Monoclonal antibodies targeting programmed death ligand 1 (PD?L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI?H) tumors must be delivered b...

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance

Notwithstanding the numerous drugs available for liver cancer, emerging evidence suggests that chemotherapeutic resistance is a significant issue. HGF and its receptor MET play critical roles ...

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cytokine, induces antitumor effects depending on CD8+ T cells. However, it remains elusive how ...

Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediate...

Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

Recently, various immuno-PET tracers based on monoclonal antibodies (mAbs),engineered scaffold proteins, and peptides were developed to target either programmed cell death protein 1 (PD-1) or programm...

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blockingnegative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrationsconsiderably higher than plasma levels achieve...